Prevalences of Other Non-Thyroid Autoimmune Diseases and Factor Associated with Their Presence in Ocular Myasthenia Gravis
Issued Date
2024-01-01
Resource Type
ISSN
11775467
eISSN
11775483
Scopus ID
2-s2.0-85192773976
Journal Title
Clinical Ophthalmology
Volume
18
Start Page
1125
End Page
1132
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Ophthalmology Vol.18 (2024) , 1125-1132
Suggested Citation
Anutraungkool T., Padungkiatsagul T., Jindahra P., Vanikieti K. Prevalences of Other Non-Thyroid Autoimmune Diseases and Factor Associated with Their Presence in Ocular Myasthenia Gravis. Clinical Ophthalmology Vol.18 (2024) , 1125-1132. 1132. doi:10.2147/OPTH.S458979 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98373
Title
Prevalences of Other Non-Thyroid Autoimmune Diseases and Factor Associated with Their Presence in Ocular Myasthenia Gravis
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: To report the prevalences of other non-thyroid autoimmune diseases and identify factors associated with their presence in ocular myasthenia gravis (OMG) subjects. Subjects and Methods: A total of 208 subjects with OMG diagnosis were included. Demographic data, clinical characteristics, the ice-pack test, the acetylcholine receptor (AChR) antibody test, electrophysiology tests (single-fiber electromyography and repetitive nerve stimulation), the presence of thymoma, generalized myasthenia gravis conversion, and the presence of other non-thyroid autoimmune diseases (defined as the presence of at least one other non-thyroid autoimmune disease) were retrospectively reviewed. Factors associated with the presence of other non-thyroid autoimmune diseases were analyzed by univariate and multivariate logistic regression. Results: Of the total 208 subjects, 21 (10.10%) exhibited the presence of other non-thyroid autoimmune diseases (19 subjects (9.14%) and 2 subjects (0.96%) had one and two other non-thyroid autoimmune diseases, respectively), and systemic lupus erythematosus (SLE) was diagnosed in 9 subjects, followed by Sjogren’s syndrome (7 subjects), rheumatoid arthritis (6 subjects), and ankylosing spondylitis (1 subject). Therefore, the prevalences of SLE, Sjogren’s syndrome, rheumatoid arthritis, and ankylosing spondylitis in OMG subjects were estimated to be 4.33% (95% confidence interval (CI): 2.29–8.02%), 3.37% (95% CI: 1.64–6.79%), 2.88% (95% CI: 1.33–6.14%), and 0.48% (95% CI: 0.08–2.67%), respectively. Positivity of the AChR antibody was the only significant factor associated with the presence of other non-thyroid autoimmune diseases (odds ratio 4.10, 95% CI: 1.11–15.21, p = 0.035). Conclusions: The presence of other non-thyroid autoimmune diseases was found in approximately 10% of OMG patients, with SLE displaying the highest prevalence. We recommend screening and monitoring for other non-thyroid autoimmune diseases in OMG patients, particularly those with positivity of the AChR antibody.